This program is developing a potential inhaled therapy to deliver normal CFTR messenger RNA to the lungs. Delivery of CFTR-encoded mRNA would allow the lung cells to create normally functioning CFTR protein, regardless of an individual’s specific CFTR gene mutation.
Laboratory studies to develop and test this potential therapy are underway.
This program is sponsored by Arcturus Therapeutics and is partially funded by the Cystic Fibrosis Foundation.
Contact us about Arcturus >